No

Antifungal Agent, Vaginal

Local treatment of vulvovaginal candidiasis

C

Known hypersensitivity to terconazole or components of the vaginal cream or suppository

Should be discontinued if sensitization or irritation occurs. Microbiological studies (KOH smear and/or cultures) should be repeated in patients not responding to terconazole in order to confirm the diagnosis and rule out other other pathogens.

1% to 10%: Genitourinary: Vulvar/vaginal burning

No data reported

Room temperature (13°C to 30°C/59°F to 86°F)

Triazole ketal antifungal agent; involves inhibition of fungal cytochrome P-450. Specifically, terconazole inhibits cytochrome P-450-dependent 14-alpha-demethylase which results in accumulation of membrane disturbing 14-alpha-demethylsterols and ergosterol depletion.

Absorption: Extent of systemic absorption after vaginal administration may be dependent on the presence of a uterus; 5% to 8% in women who had a hysterectomy versus 12% to 16% in nonhysterectomy women

Adults: Female: Insert 1 applicatorful intravaginally at bedtime for 7 consecutive days

No information available to require special precautions

No effects or complications reported

Complete full course of therapy as directed. Insert vaginally as directed by prescriber or see package insert. Sexual partner may experience irritation of penis; best to refrain from intercourse during period of treatment. Report persistent vaginal burning, itching, irritation, or discharge. Pregnancy/breast-feeding precautions: Inform prescriber if you are or intend to be pregnant. Consult prescriber if breast-feeding.

Watch for local irritation; assist patient in administration, if necessary; assess patient's ability to self-administer, may be difficult in patients with arthritis or limited range of motion

Cream, vaginal: 0.4% (45 g); 0.8% (20 g)

Suppository, vaginal: 80 mg (3s)

Drug Facts and Comparisons, St Louis, MO: 1989, 528-9.